Regenerative Medical Technology (RMTG) FCF Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted FCF Margin of 7.17% for Q2 2026, up 188.75% on a QoQ basis from 8.08% in Q1 2026, and up 6800.0% year-over-year from 0.1% in Q2 2025.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) FCF Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology has reported FCF Margin for 9 years, with the latest figure at 7.17% in Q2 2026.
- On a quarterly basis, FCF Margin rose 6800.0% year-over-year to 7.17% in Q2 2026; TTM through Jun 2026 was 6.19%, a 635.0% decrease from a year earlier, with the FY2025 full-year figure at 25.67%, down 4113.0% from the prior year.
- FCF Margin was 7.17% for Q2 2026 at Regenerative Medical Technology, up from 8.08% in the prior quarter.
- The five-year high for FCF Margin was 22.24% in Q3 2024, with the low at 172.78% in Q1 2022.
- Average FCF Margin over 5 years is 33.99%, with a median of 13.56% recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: FCF Margin surged 342996 bps in 2022, then slumped 6558 bps in 2025.
- Over 5 years, FCF Margin stood at 33.1% in 2022, then plunged by 54 bps to 50.91% in 2023, then surged by 143 bps to 21.8% in 2024, then sank by 167 bps to 14.57% in 2025, then surged by 149 bps to 7.17% in 2026.
- The last three FCF Margin figures came in at 7.17% (Q2 2026), 8.08% (Q1 2026), and 14.57% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | -13,981.63% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.95 Bn | 1.78 Bn | 56.40 Mn | 18.67% |
| 10 | Regenerative Medical Technology | 1.18 Mn | -139,694.93 | 2.58 Mn | 7.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.17% |
| Mar 31, 2026 | -8.08% |
| Dec 31, 2025 | -14.57% |
| Sep 30, 2025 | -36.30% |
| Jun 30, 2025 | -60.82% |
| Mar 31, 2025 | 4.19% |
| Dec 31, 2024 | 21.80% |
| Sep 30, 2024 | 22.24% |
| Jun 30, 2024 | 4.76% |
| Mar 31, 2024 | 5.97% |
| Dec 31, 2023 | -50.91% |
| Sep 30, 2023 | -12.56% |
| Jun 30, 2023 | -113.86% |
| Mar 31, 2023 | 0.16% |
| Dec 31, 2022 | -33.10% |
| Sep 30, 2022 | -41.67% |
| Jun 30, 2022 | -133.38% |
| Mar 31, 2022 | -172.78% |
| Dec 31, 2021 | -3,463.06% |
| Sep 30, 2021 | -260.94% |